The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
Open accessAbstract
Background Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overall survival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in a compassionate-use program.Patients and methods In this prospective study, patients were treated between June 2010 and September 2011. Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy, and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kg every 3 weeks.Results Seventy-three patients were included. Median OS was 9.1 months (95% CI 6.4-11.3) from the start of ipilimumab. Immune-related adverse events were observed in 45 patients (62%), including 19 grade 3-4 events (26%). No drug-related death occurred. A lymphocyte count >1000/mm(3) at the start of the second course and an increase in the eosinophil count >100/mm(3) between the first and second infusions were correlated with an improved OS.Conclusion Ipilimumab toxic effect is manageable in real life. Biological data such as lymphocyte and eosinophil counts at the time of the second ipilimumab infusion appear to be early markers associated with better OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEstimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,032
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova‐Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,323
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Management of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 869
Research works printed but not linked: 1
- Squibb, 2011, YERVOY™ (ipilimumab) Immune-mediated adverse reaction management guide
Cited by
Sorted by citations
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,782
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 998
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 706
Self-citationGolden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 691
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
“org Clin Cancer Res; 22(12) June 15, 2016 2913”
BackgroundResultInfluentialImmune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 523
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 486
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente‐Casares, X., Tsai, S. J., Yang, Y., & Santamaría, P. (2014) · ACS Nano · doi:10.1021/nn5062029 · Cited by 477
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
Belum, V. R., Benhuri, B., Postow, M. A., Hellmann, M. D., Lesokhin, A. M., Segal, N. H., Motzer, R. J., Wu, S., Busam, K. J., Wolchok, J. D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.010 · Cited by 418
Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Vecchio, M. D., Maio, M., Cappellini, G. C. A., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw016 · Cited by 407
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Ménétrier‐Caux, C., Ray-Coquard, I. L., Blay, J., & Caux, C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0549-5 · Cited by 359
Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 316
Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.467 · Cited by 308
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E., de Groot, J. W. B., Soetekouw, P. M. M. B., Jansen, R. L. H., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1528-9 · Cited by 307
Eosinophils: The unsung heroes in cancer?
Varricchi, G., Galdiero, M. R., Loffredo, S., Lucarini, V., Marone, G., Mattei, F., Marone, G., & Schiavoni, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393134 · Cited by 288
Zimmer, L., Vaübel, J., Mohr, P., Hauschild, A., Utikal, J. S., Simon, J. C., Garbe, C., Herbst, R. A., Enk, A., Kämpgen, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118564 · Cited by 270
Ferrucci, P. F., Gandini, S., Battaglia, A., Alfieri, S., Giacomo, A. M. D., Giannarelli, D., Cappellini, G. C. A., Galitiis, F. D., Marchetti, P., Amato, G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.180 · Cited by 274
Tirumani, S. H., Ramaiya, N. H., Keraliya, A. R., Bailey, N., Ott, P. A., Hodi, F. S., & Nishino, M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0102 · Cited by 257
Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1545-8 · Cited by 253
Checkpoint blocking antibodies in cancer immunotherapy
Kyi, C., & Postow, M. A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.10.015 · Cited by 246
Diehl, A., Yarchoan, M. M., Hopkins, A., Jaffee, E. M., & Grossman, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.23217 · Cited by 249
Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236
Postow, M. A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S., Tanneau, I., Noel, M., Courtier, A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0070-4 · Cited by 232
Tanizaki, J., Haratani, K., Hayashi, H., Chiba, Y., Nakamura, Y., Yonesaka, K., Kudo, K., Kaneda, H., Hasegawa, Y., Tanaka, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.030 · Cited by 227
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Blomberg, O. S., Spagnuolo, L., Garner, H., Voorwerk, L., Isaeva, O. I., van Dyk, E., Bakker, N. A. M., Chalabi, M., Klaver, C., Duijst, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.014 · Cited by 225
Tobin, R. P., Jordan, K. R., Robinson, W. A., Davis, D. M., Borges, V. F., Gonzalez, R. C., Lewis, K. D., & McCarter, M. D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.007 · Cited by 210
Limagne, E., Richard, C., Thibaudin, M., Fumet, J.-D., Truntzer, C., Lagrange, A., Favier, L., Coudert, B. P., & Ghiringhelli, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1564505 · Cited by 211
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin, R., Netti, G. S., Spadaccino, F., Porta, C., Gesualdo, L., Stallone, G., Castellano, G., & Ranieri, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574271 · Cited by 208
Lucarini, V., Ziccheddu, G., Macchia, I., Sorsa, V. L., Peschiaroli, F., Buccione, C., Sistigu, A., Sanchez, M., Andreone, S., D’Urso, M. T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1317420 · Cited by 199
Predictors of responses to immune checkpoint blockade in advanced melanoma
Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00608-2 · Cited by 200
Self-citationClinical activity of ipilimumab for metastatic uveal melanoma
Luke, J. J., Callahan, M. K., Postow, M. A., Romano, E., Ramaiya, N. H., Bluth, M. J., Giobbie‐Hurder, A., Lawrence, D. P., Ibrahim, N., Ott, P. A., et al. (2013) · Cancer · doi:10.1002/cncr.28282 · Cited by 192
Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy
Guerra, L., Bonetti, L., & Brenner, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107848 · Cited by 194
Fizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.07.032 · Cited by 185
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot, J., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A.-L., Ebbo, M., Godeau, B., Michel, M., Ribrag, V., & Lambotte, O. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.014 · Cited by 184
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0249 · Cited by 180
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 183
Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A. M., Jankú, F., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0534-0 · Cited by 179
Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management
Naik, P. P. (2021) · World Journal of Oncology · doi:10.14740/wjon1349 · Cited by 195
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179
Suh, K. J., Kim, S. H., Kim, Y. J., Kim, M., Keam, B., Kim, T. M., Kim, D., Heo, D. S., & Lee, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2092-x · Cited by 172
Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., Abe, T., Funakoshi, T., Yamamoto, N., Amagai, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12677 · Cited by 168
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H. E. K., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 166
Hannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaı̈b, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.3 · Cited by 166
Self-citationPD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Luke, J. J., & Ott, P. A. (2015) · Oncotarget · doi:10.18632/oncotarget.2980 · Cited by 159
Zaragoza, J., Caille, A., Bénéton, N., Bens, G., Christiann, F., Maillard, H., & Machet, L. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14155 · Cited by 154
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Barker, C. A., Postow, M. A., Khan, S. A., Beal, K. P., Parhar, P. K., Yamada, Y. J., Lee, N. Y., & Wolchok, J. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0082 · Cited by 147
Moreira, A., Leisgang, W., Schuler, G., & Heinzerling, L. (2017) · Immunotherapy · doi:10.2217/imt-2016-0138 · Cited by 147
Immune modulation for cancer therapy
Naidoo, J., Page, D. B., & Wolchok, J. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.348 · Cited by 148
Soyano, A. E., Dholaria, B., Marin-Acevedo, J. A., Diehl, N. N., Hodge, D. O., Luo, Y., Manochakian, R., Chumsri, S., Adjei, A. A., Knutson, K. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0447-2 · Cited by 142
Chu, X., Zhao, J., Zhou, J., Zhou, F., Jiang, T., Jiang, S., Sun, X., You, X., Wu, F., Ren, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.015 · Cited by 148
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 148
D’Angelo, S. P., Shoushtari, A. N., Keohan, M. L., Dickson, M. A., Gounder, M. M., Chi, P., Loo, J. K., Gaffney, L., Schneider, L., Patel, Z. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2349 · Cited by 133
Hannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaı̈b, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.28 · Cited by 135
Self-citationWagner, N. B., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0167-x · Cited by 129
Rosner, S., Kwong, E., Shoushtari, A. N., Friedman, C. F., Warner, A. B., Brady, M. S., Coit, D. G., Callahan, M. K., Wolchok, J. D., Chapman, P. B., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1356 · Cited by 127
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 118
Emerging Roles for Eosinophils in the Tumor Microenvironment
Reichman, H., Karo-Atar, D., & Munitz, A. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.002 · Cited by 116
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2014) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
Richtig, G., Höeller, C., Wolf, M., Wolf, I. H., Rainer, B. M., Schulter, G., Richtig, M., Grübler, M. R., Gappmayer, A., Haidn, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204729 · Cited by 111
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 115
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H., & Svane, I. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.017 · Cited by 105
Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment
Sun, H., Wang, S. L., Yan, S., Zhang, Y., Nelson, P. J., Jia, H., Qin, L., & Dong, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01104 · Cited by 109
Fujisawa, Y., Yoshino, K., Otsuka, A., Funakoshi, T., Fujimura, T., Yamamoto, Y., Hata, H., Gosho, M., Tanaka, R., Yamaguchi, K., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.07.007 · Cited by 101
Andreone, S., Spadaro, F., Buccione, C., Mancini, J., Tinari, A., Sestili, P., Gambardella, A. R., Lucarini, V., Ziccheddu, G., Parolini, I., et al. (2019) · Cancers · doi:10.3390/cancers11111664 · Cited by 91
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
Simon, S. C. S., Hu, X., Panten, J., Grees, M., Renders, S., Thomas, D., Weber, R., Schulze, T. J., Utikal, J. S., & Umansky, V. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1727116 · Cited by 88
Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Groß, S., Erdmann, M., Haendle, I., Voland, S., Berger, T. G., Schultz, E. S., Strasser, E. F., Dankerl, P., Janka, R., Schliep, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91438 · Cited by 89
Petrelli, F., Ardito, R., Merelli, B., Lonati, V., Cabiddu, M., Seghezzi, S., Barni, S., & Ghidini, A. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000520 · Cited by 89
Current status and perspectives in immunotherapy for metastatic melanoma
Marconcini, R., (IMI), F. T. I. M. I., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. D., Picasso, V., Guardo, L. D., Cimminiello, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23746 · Cited by 84
Khoja, L., Atenafu, E. G., Templeton, A. J., Qye, Y., Chappell, M. A., Saibil, S. D., Hogg, D., Butler, M. O., & Joshua, A. M. (2016) · Cancer Medicine · doi:10.1002/cam4.878 · Cited by 82
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Lü, Z., Peng, Z., Liu, C. X., Wang, Z., Wang, Y., Jiao, X., Li, J., & Shen, L. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100041 · Cited by 81
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier, A., Jeanville, P., Champiat, S., Lazarovici, J., Voisin, A.-L., Mateus, C., Lambotte, O., Annereau, M., & Michot, J.-M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.017 · Cited by 78
Self-citationImmune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies
Eggermont, A. M. M., Maio, M., & Robert, C. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.010 · Cited by 80
Self-citationBiomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 77
Fässler, M., Diem, S., Mangana, J., Ali, O. H., Berner, F., Bomze, D., Ring, S. S., Niederer, R., Gil‐Cruz, C., Perez‐Shibayama, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0523-2 · Cited by 77
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
Chan, K. K., MAGRO, C. M. J., Shoushtari, A. N., Rudin, C. M., Rotemberg, V. M., Rossi, A., Lezcano, C. M., Carrino, J. A., Fernández, D., Postow, M. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0508 · Cited by 76
Qian, Z., Zhu, G., Tang, L., Wang, M., Zhang, L., Fu, J., Huang, C., Fan, S., Sun, Y., Lv, J., et al. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22196 · Cited by 75
Clinical Development of Immune Checkpoint Inhibitors
Ito, A., Kondo, S., Tada, K., & Kitano, S. (2015) · BioMed Research International · doi:10.1155/2015/605478 · Cited by 79
Zimmer, L., Eigentler, T., Kiecker, F., Simon, J. C., Utikal, J. S., Mohr, P., Berking, C., Kämpgen, E., Dippel, E., Stadler, R., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0716-5 · Cited by 74
Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111607 · Cited by 78
Cheng, J., Luo, W., Sun, C., Jin, Z., Zeng, X., Alexander, P. B., Gong, Z., Xia, X., Ding, X., Xu, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc7609 · Cited by 76
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
Lanitis, E., Irving, M. B., & Coukos, G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01187-w · Cited by 81
Wistuba‐Hamprecht, K., Martens, A., Haehnel, K., Foppen, M. G., Yuan, J. D., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dréno, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.001 · Cited by 75
CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Zheng, X., Zhang, N., Qian, L., Wang, X., Fan, P., Kuai, J., Lin, S., Liu, C., Jiang, W., Qin, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32829 · Cited by 76
Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers
Inthagard, J., Edwards, J., & Roseweir, A. K. (2019) · Clinical Science · doi:10.1042/cs20181003 · Cited by 70
An, Y., Jiang, W., Kim, B. Y. S., Qian, J. M., Tang, C. Z., Fang, P., Logan, J. K., D’Souza, N. M., Haydu, L. E., Wang, X. A., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.08.009 · Cited by 69
on behalf of the Cancer Immunotherapy Trials Network (CITN), Kohrt, H. E. K., Tumeh, P. C., Benson, D., Bhardwaj, N., Brody, J., Formenti, S. C., Fox, B. A., Galon, J., June, C. H., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0118-0 · Cited by 69
Self-citation
Metadata
- Authors
- Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C.
- Affiliations
- Institut Gustave Roussy (FR)
- Université Paris-Sud (FR)
- Inserm (FR)
- Corresponding author
- Delyon, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 24
- Issue
- 6
- Pages
- 1697-1703
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2107863654
- Semantic Scholar
- 227acc6dc2205788c75d438e03d62ffe4cfd3073
- Cited by
- 318
- References
- 23
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 10 · 2023: 11 · 2022: 21 · 2021: 28 · 2020: 36 · 2019: 31 · 2018: 31 · 2017: 43 · 2016: 36 · 2015: 32 · 2014: 13 · 2013: 9
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, immune checkpoint inhibitors, overall survival, lymphocyte count, eosinophil count, immune-related adverse events, prognostic factors, compassionate use program
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Eosinophils, Female, Humans, Lymphocytes, Male, Melanoma, Middle Aged, Prospective Studies, Skin Neoplasms, Time Factors, Survival Rate, Treatment Outcome, Lymphocyte Count, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
